David Roman

Travis Steed

Caitlin Cronin

Richard Newitter

Robert Marcus

Christopher Pasquale

Danielle Antalffy

Frederick Wise

Jeffrey Johnson

Matthew O'Brien

Matthew Taylor

Michael Matson

Patrick Wood

Ryan Zimmerman

Shagun Singh Chadha

Steven Lichtman

Vikramjeet Chopra

Allen

Chris Pasquale

Jason Wittes

Jayson Bedford

Joanne Wuensch

Joshua Jennings

Larry Biegelsen

Lawrence Biegelsen

Matthew Miksic

Matt Miksic

Shagun Singh

Sophie Kanon

Vijay Kumar

- Zimmer Biomet's **iodine-treated total hip replacement system** received **FDA Breakthrough Device Designation** on **October 28, 2025**.  **[1136869_20251028DE08228:0]** 
- This is the **first product in Zimmer Biomet history** to receive this designation.  **[1136869_20251028DE08228:0]** 
- The system integrates iodine technology into the iTaperloc® Complete and iG7™ Hip System to help address challenges associated with **Periprosthetic Joint Infections (PJI)** for patients at higher risk of infection.  **[1136869_20251028DE08228:0]** 
- It previously received approval from the **Japan PMDA in September**, becoming the **world's first approved orthopedic implant with Iodine Technology**.  **[1136869_20251028DE08228:0]** 
- The FDA's Breakthrough Devices Program offers a **prioritized review of submissions**.  **[1136869_20251028DE08228:0]**

Zimmer Biomet Receives FDA Breakthrough Designation for Hip Replacement System

- **Zimmer Biomet Holdings, Inc.** completed the acquisition of **Monogram Technologies Inc.**, an AI-driven orthopedic robotics company, on **October 7, 2025**.  **[1136869_0001193125-25-233473_d938765dex991.htm:0]** **[1136869_0001193125-25-233473_d938765d8k.htm:1]** 
- This acquisition is intended to expand Zimmer Biomet's orthopedic robotics portfolio, aiming to offer the **first fully autonomous robotic solution** for orthopedic procedures.  **[1136869_0001193125-25-233473_d938765dex991.htm:0]** 
- Monogram's **CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology received FDA 510(k) clearance in March 2025** and is expected to be commercialized by **early 2027**.  **[1136869_0001193125-25-233473_d938765dex991.htm:0]** 
- Monogram common stockholders received **$4.04 in cash** per share and **contingent value rights (CVRs)** entitling them to receive up to **$12.37 in cash** if certain milestones are achieved through 2030.  **[1136869_0001193125-25-233473_d938765dex991.htm:0]** **[1136869_0001193125-25-233473_d938765d8k.htm:1]**

Zimmer Biomet Completes Acquisition of Monogram Technologies

- Zimmer Biomet Holdings, Inc. **completed the acquisition of Monogram Technologies Inc.** on **October 7, 2025**, integrating an **AI-driven, next-generation orthopedic robotics company** into its portfolio.  **[1136869_20251007DE91697:0]** 
- The acquisition is expected to provide Zimmer Biomet with **new and differentiated capabilities** in orthopedic robotics, aiming to offer the **first fully autonomous robotic solution** in the orthopedic market.  **[1136869_20251007DE91697:0]** 
- Monogram's semi-autonomous total knee arthroplasty (TKA) robotic technology received **FDA 510(k) clearance in March 2025** and is slated for commercialization with Zimmer Biomet implants by **early 2027**.  **[1136869_20251007DE91697:0]** 
- Monogram shareholders received **$4.04 in cash per share** and contingent value rights (CVRs) for up to an additional **$12.37 in cash**, contingent on achieving specific milestones through 2030.  **[1136869_20251007DE91697:0]**

- Zimmer Biomet announced that the **Pharmaceutical and Medical Devices Agency (PMDA) in Japan approved** its **iTaperloc® Complete and iG7™ Hip System** on September 25, 2025.  **[1136869_20250925DE83669:0]** 
- This system is the **world's first approved orthopedic implant with Iodine Technology**, which inhibits bacterial adhesion and prevents biofilm formation on the implant surface.  **[1136869_20250925DE83669:0]** 
- The Iodine Technology is designed to address **Periprosthetic Joint Infection (PJI)**, a significant complication estimated to occur in **1-2% of primary total joint arthroplasty procedures**.  **[1136869_20250925DE83669:0]** 
- This approval strengthens Zimmer Biomet's **infection management solutions portfolio** and marks a key milestone in its new product cycle.  **[1136869_20250925DE83669:0]**

Zimmer Biomet Receives Japan PMDA Approval for First Iodine-Treated Hip Replacement System

ZIMMER BIOMET HOLDINGS (ZBH)